Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker

BioTechniques

Volumn 39, Issue 5, 2005, Pages 665-670

  Sánchez Puig, Juana M ^a   Blasco, Rafael ^a  

^a INIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; BIOMARKERS; BIOMATERIALS; GENES; STRAIN; VIRUSES;

CELL-TO-CELL SPREAD; MODIFIED VACCINIA ANKARA (MVA); RECOMBINANTS; VACCINE VECTOR;

VACCINES;

RECOMBINANT VACCINE; GREEN FLUORESCENT PROTEIN; MEMBRANE PROTEIN; P37 PROTEIN, VACCINIA VIRUS; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ARTICLE; BIOSAFETY; CELL STRAIN BHK; CLONING VECTOR; F13L GENE; GENE DELETION; GENE EXPRESSION; KNOCKOUT GENE; MARKER GENE; NONHUMAN; VACCINIA VIRUS; VACCINIAVIRUS VECTOR; VIRUS ISOLATION; VIRUS PLAQUE; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; CELL LINE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC MARKER; GENETIC PROCEDURES; GENETIC RECOMBINATION; GENETICS; HAMSTER; METABOLISM; METHODOLOGY; MOLECULAR CLONING; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PLASMID; SEQUENCE HOMOLOGY; TIME; TRANSGENE; WESTERN BLOTTING;

ANIMALIA; CRICETINAE; EUKARYOTA; VACCINIA VIRUS;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; CLONING, MOLECULAR; CRICETINAE; GENE DELETION; GENE EXPRESSION REGULATION, VIRAL; GENETIC MARKERS; GENETIC TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; PLASMIDS; RECOMBINATION, GENETIC; SEQUENCE HOMOLOGY, NUCLEIC ACID; TIME FACTORS; TRANSGENES; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 33644878630     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/000112012     Document Type: Article

References (20)

1. Stickl, H., V. Hochstein-Mintzel, A. Mayr, H.C. Huber, H. Schafer, and A. Holzner. 1974. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl). Dtsch. Med. Wochenschr. 99:2386-2392.
2. Hochstein-Mintzel, V., T. Hanichen, H.C. Huber, and H. Stickl. 1975. An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author's transl). Zentralbl. Bakteriol. [Orig A] 250:283-297.
3. Moss, B., M.W. Carroll, L.S. Wyatt, J.R. Bennink, V.M. Hirsch, S. Goldstein, W.R. Elkins, T.R. Fuerst, et al. 1996. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. 397:7-13.
4. Sutter, G. and C. Staib. 2003. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3:263-271.
5. Carroll, M.W. and B. Moss. 1997. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238:198-211.
6. Drexler, I., K. Heller, B. Wahren, V. Erfle, and G. Sutter. 1998. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79:347-352.
7. Schneider, J., S.C. Gilbert, T.J. Blanchard, T. Hanke, K.J. Robson, C.M. Hannan, M. Becker, R. Sinden, et al. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402.
8. Sutter, G., M. Ohlmann, and V. Erfle. 1995. Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase. FEBS Lett. 371:9-12.
9. Staib, C., I. Drexler, M. Ohlmann, S. Wintersperger, V. Erfle, and G. Sutter. 2000. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. BioTechniques 28:1137-1148.
10. Staib, C., M. Lowel, V. Erfle, and G. Sutter. 2003. Improved host range selection for recombinant modified vaccinia virus Ankara. BioTechniques 34:694-700.
11. Staib, C., I. Drexler, and G. Sutter. 2004. Construction and isolation of recombinant MVA. Methods Mol. Biol. 269:77-100.
12. Sutter, G., A. Ramsey Ewing, R. Rosales, and B. Moss. 1994. Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J. Virol. 68:4109-4116.
13. Hornemann, S., O. Harlin, C. Staib, S. Kisling, V. Erfle, B. Kaspers, G. Hacker, and G. Sutter. 2003. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J. Virol. 77:8394-8407.
14. Blasco, R. and B. Moss. 1995. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158:157-162.
15. Blasco, R. and B. Moss. 1991. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-dalton outer envelope protein. J. Virol. 65:5910-5920.
16. Blasco, R. and B. Moss. 1992. Role of cell-associated enveloped vaccinia virus in cell-to-cell virus spread. J. Virol. 66:4170-4179.
17. Earl, P. and B. Moss. 1991. Expression of proteins in mammalian cells using vaccinia viral vectors. In F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl (Eds.), Current Protocols in Molecular Biology. Wiley-Interscience, New York.
18. Lorenzo, M.M., I. Galindo, and R. Blasco. 2004. Construction and isolation of recombinant vaccinia virus using genetic markers. Methods Mol. Biol. 269:15-30.
19. Sanchez-Puig, J.M., L. Sanchez, G. Roy, and R. Blasco. 2004. Susceptibility of different leukocyte cell types to Vaccinia virus infection. Virol. J. 1:10.
20. Barcena, J., M.M. Lorenzo, J.M. Sanchez-Puig, and R. Blasco. 2000. Sequence and analysis of a swinepox virus homologue of the vaccinia virus major envelope protein P37 (F13L). J. Gen. Virol. 87:1073-1085.